Novo Nordisk to issue Euro medium term notes worth up to EUR 5bn

On Friday, Denmark's largest pharmaceutical company announced the establishment of an EMTN program in which the company provides a framework for issuing unsecured notes worth billions of euros. The company states the proceeds will be put towards "general corporate purposes".

Photo: Stine Tidsvilde

The hunt for capital for general corporate purposes has led Novo Nordisk to establish a Euro Medium Term Note (EMTN) program through which it can issue unsecured notes up to an aggregated principal amount of EUR 5bn (USD 6.1m), according to a Friday press release from the firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs